Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response
1Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Background:
Poor drug response of sorafenib is a major challenge which reduces clinical benefit of renal cell carcinoma (RCC) patients. It is therefore of great clinical significance to elucidate the underlying mechanism to restore the therapeutic response to sorafenib.
Methods:
Angiopoietin-like protein 3 (ANGPTL3) protein levels were measured by western blot and immunohistochemistry in two cohorts of RCC patients. Loss-of-function and gain-of-function experiments were performed to investigate the biological roles of ANGPTL3 in response to sorafenib treatment in RCC cells. Human proteome microarray and immunoprecipitation analysis were performed to explore the molecular mechanisms underlying the functions of ANGPTL3.
Results:
ANGPTL3 was upregulated in sorafenib-responsive RCC, which correlated with clinically good sorafenib response. Knockdown of ANGPTL3 conferred sorafenib-tolerance traits to RCC cells, whereas overexpression of ANGPTL3 restored sorafenib sensitivity in RCC cells. Mechanistically, ANGPTL3 bound to Focal Adhesion Kinase(FAK) and restained sorafenib induced nuclear translocation of FAK, leading to attenuate the ubiquitination of p53, which contributed to cellular apoptosis and enhanced sorafenib response.
Conclusions:
ANGPTL3 may be a novel predictor for the response of sorafenib therapy in RCC patients, and a potential target in improving its therapeutic effect.
Insights
Angiopoietin-like protein 3 (ANGPTL3) predicts sorafenib response in renal cell carcinoma (RCC). Upregulating ANGPTL3 enhances sorafenib sensitivity by inhibiting FAK, improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Sorafenib resistance is a significant clinical challenge for renal cell carcinoma (RCC) patients.
- Understanding mechanisms of sorafenib resistance is crucial for improving therapeutic outcomes.
Purpose of the Study:
- To investigate the role of Angiopoietin-like protein 3 (ANGPTL3) in sorafenib response in RCC.
- To elucidate the underlying molecular mechanisms by which ANGPTL3 influences sorafenib efficacy.
Main Methods:
- ANGPTL3 protein levels were assessed in RCC patient cohorts using western blot and immunohistochemistry.
- Loss-of-function and gain-of-function experiments were conducted in RCC cells to evaluate ANGPTL3's biological roles.
- Proteomic and immunoprecipitation analyses were employed to explore ANGPTL3's molecular interactions.
Main Results:
- ANGPTL3 was found to be upregulated in sorafenib-responsive RCC, correlating with positive clinical responses.
- Knockdown of ANGPTL3 induced sorafenib tolerance, while its overexpression restored sensitivity.
- Mechanistically, ANGPTL3 binds to Focal Adhesion Kinase (FAK), preventing sorafenib-induced FAK nuclear translocation, thereby attenuating p53 ubiquitination and promoting apoptosis.
Conclusions:
- ANGPTL3 serves as a potential predictive biomarker for sorafenib therapy response in RCC.
- ANGPTL3 represents a promising therapeutic target for overcoming sorafenib resistance and enhancing treatment efficacy.
Related Concept Videos
Nuclear Localization Signals and Import
Protein Import into the Peroxisomes
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Nuclear Protein Sorting
Proteins targeted to the nucleus carry nuclear localization signals or NLS recognized by import receptors in the cytosol. Similarly, proteins with nuclear export signals are recognized by export receptors. Import and export receptors are...
Nuclear Export of mRNA
Non-nuclear Inheritance
Regulation of Nuclear Protein Sorting


